BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 17474358)

  • 1. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choices in the treatment of cutaneous T-cell lymphoma.
    Hymes KB
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal combination with PUVA: rationale and clinical trial update.
    Stadler R
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies for cutaneous T-cell lymphomas.
    Horwitz SM
    Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jul; 6(7):757-60. PubMed ID: 17763605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel treatment modalities in cutaneous T cell lymphoma. Biologic response modifiers].
    Marschalkó M
    Orv Hetil; 2005 Jun; 146(23):1251-5. PubMed ID: 15988920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
    Chin KM; Foss FM
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):199-204. PubMed ID: 17229335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
    Klemke CD; Goerdt S
    G Ital Dermatol Venereol; 2008 Dec; 143(6):365-74. PubMed ID: 19169209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory effects of rexinoids.
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S21-5. PubMed ID: 16516672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.
    Kempf W; Kettelhack N; Duvic M; Burg G
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1405-19. PubMed ID: 14710892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycosis fungoides: pathophysiology and emerging therapies.
    Duvic M; Foss FM
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S21-8. PubMed ID: 18086343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
    Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
    Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
    J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging treatment strategies for cutaneous T-cell lymphoma.
    Lansigan F; Foss FM
    Drugs; 2010 Feb; 70(3):273-86. PubMed ID: 20166766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.